Company intelligence / Profile preview

ImmunSYS, Inc.

Fort Lauderdale, Florida, United Statesimmunsys.com ↗

Ownership: Private
Employees: ~8
Development stage: Phase 1

Overview

ImmunSYS, Inc. develops innovative intratumoral immunotherapies for late-stage metastatic prostate cancer and other solid tumors using its proprietary YourVaccx™ platform. The approach combines a novel energy delivery device with a multi-component drug regimen to stimulate the immune system to attack cancer throughout the body. The technology was developed by Dr. Gary Onik—who also benefited as a patient—and has shown promising results in initial applications.[1][2]

Therapeutic areas: Oncology
Modalities: Intratumoral immunotherapy (YourVaccx™ platform)Combination immunotherapeutic drugs[1][4]Controlled cell lysis[1]Device-based therapy (ANTIGENerator™ energy delivery device)[4]
Industry: Biotech

Drug pipeline

1 asset

YourVaccx

Phase 1

Indications: Metastatic prostate cancer, Metastatic solid tumors

Beyond the preview

Go deeper on ImmunSYS, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImmunSYS, Inc..